We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

58 hedge funds and large institutions have $440M invested in Crinetics Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

92% more capital invested

Capital invested by funds: $229M → $440M (+$211M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

9.41% more ownership

Funds ownership: 62.95% → 72.36% (+9.4%)

5% less funds holding

Funds holding: 61 → 58 (-3)

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
24
Reduced
11
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$2.09M
2
OM
Opaleye Management
Massachusetts
+$1.13M
3
State Street
State Street
Massachusetts
+$387K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$364K
5
Northern Trust
Northern Trust
Illinois
+$244K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.42M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.87M
3
Goldman Sachs
Goldman Sachs
New York
-$1.09M
4
Marshall Wace
Marshall Wace
United Kingdom
-$829K
5
Millennium Management
Millennium Management
New York
-$706K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$701K +$5.62K +295 +1%
California Public Employees Retirement System
27
California Public Employees Retirement System
California
$479K +$364K +19,100 New
Millennium Management
28
Millennium Management
New York
$453K -$706K -37,108 -67%
Swiss National Bank
29
Swiss National Bank
Switzerland
$449K – – –
Morgan Stanley
30
Morgan Stanley
New York
$437K -$2.49K -131 -0.7%
UBS Group
31
UBS Group
Switzerland
$429K +$150K +7,888 +86%
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$427K – – –
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$416K – – –
Bank of America
34
Bank of America
North Carolina
$326K +$32.2K +1,690 +15%
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$319K – – –
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$319K +$1.37K +72 +0.6%
AllianceBernstein
37
AllianceBernstein
Tennessee
$296K +$11.4K +600 +5%
Barclays
38
Barclays
United Kingdom
$281K +$99.3K +5,215 +87%
HF
39
HRT Financial
New York
$265K +$201K +10,582 New
Wells Fargo
40
Wells Fargo
California
$232K -$267K -14,034 -60%
PP
41
Paloma Partners
Connecticut
$210K +$159K +8,369 New
Rockefeller Capital Management
42
Rockefeller Capital Management
New York
$177K +$77.2K +4,053 +135%
AIG
43
American International Group
New York
$173K -$1.1K -58 -0.8%
HTC
44
Hershey Trust Company
Pennsylvania
$169K – – –
MIM
45
MetLife Investment Management
New Jersey
$146K +$111K +5,835 New
CSS
46
Cubist Systematic Strategies
Connecticut
$118K +$55.6K +2,922 +164%
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$105K +$79.4K +4,173 New
Deutsche Bank
48
Deutsche Bank
Germany
$100K +$17.5K +919 +30%
JP Morgan Chase
49
JP Morgan Chase
New York
$95K +$419 +22 +0.6%
JCM
50
Jacobi Capital Management
Pennsylvania
$75K – – –
1
2
3

CRNX Hedge Fund Activity: Q4 2019 in Review

58 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2019, worth a combined $440M — up 92% from $229M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRNX positions and 7 closed out — a net gain of 2 holders — while 24 added to existing stakes and 11 trimmed.

The largest buyer was Polar Capital, adding an estimated $2.09M. The largest seller was BlackRock, cutting an estimated $4.42M.

  • 58 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2019, down from 61 in Q3 2019.
  • Funds reported $440M of Crinetics Pharmaceuticals stock for Q4 2019, up 92% quarter-over-quarter.
  • 9 funds opened new Crinetics Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +2 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2019 was Polar Capital, an estimated $2.09M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $4.42M sold.

Based on aggregated 13F filings for Q4 2019.